Press
| sort by | name | file type | date |
|
Positive appraisal from the All Wales Medicines Strategy Group (AWMSG) for Ratiograstim®
.pdf | 82.3 kB | 29.01.2010 ratiopharm direct are delighted to announce that our biosimilar filgrastim, Ratiograstim® has received the following positive appraisal from the All Wales Medicines Strategy Group (AWMSG). The Final Appraisal Report is now available on the AWMSG website. download... |
 |
|
|
|
Positive appraisal from the Scottish Medicines Consortium for Ratiograstim®
.pdf | 82.3 kB | 29.01.2010 ratiopharm direct are delighted to announce that our biosimilar filgrastim, Ratiograstim® has received a positive appraisal from the Scottish Medicines Consortium. download... |
|
|
|
|
Press release: Biosimilar Ratiograstim® receives EMEA approval First biosimilar for the treatment of neutropenia .pdf | 39.0 kB | 05.02.2009 Ulm, September 2008. ratiopharm has received approval for the first filgrastim biosimilar from the EU regulatory office, EMEA. The market launch of Ratiograstim® will take place in the fourth quarter of 2008. “This first biosimilar to be launched on the market by the ratiopharm Group is backed by 125 years of experience in research and development and underscores ratiopharm’s position as an innovative generics company,” said ratiopharm Group CEO Oliver Windholz. download... |
|
|